In 2016, Ipsen’s R&D expenditure totaled close to €209 million, representing more than 13% of Group sales.

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules, including small molecules, neurotoxins and theranostics.

Updated 2017 April 15th

tableau Pipeline
Last update 15/04/2017